Seeing the Person, Not the Illness: Promoting Diabetes Medication Adherence Through Patient-Centered Collaboration

Schwartz, David D.; Stewart, Sean D.; Aikens, James E.; Bussell, Jennifer K.; Osborn, Chandra Y.; Safford, Monika M.

doi:10.2337/cd16-0007

Cited by 27 publications

(25 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such accord between providers and patients around the initiation of insulin may provide a foundation for better persistence later on. [27][28][29][30][31][32][33][34] This process may also endow continuers with a sense of responsibility to better self-manage, find solutions for their own care, and to report fewer concerns and specific challenges after initiation. [35][36][37] Experienced or potential weight gain and hypoglycemia are among the top reported reasons to interrupt or discontinue treatment.…”

Section: Discussionmentioning

confidence: 99%

<p>Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States</p>

Kalirai

Ivanova

Pérez-Nieves

et al. 2020

DMSO

View full text Add to dashboard Cite

Objective: A survey of US adults with type 2 diabetes mellitus was conducted to better understand patients' insulin initiation experiences and treatment persistence behaviors. Research Design and Methods: Participants were recruited from consumer panels and grouped by basal insulin treatment pattern: continuers (no gap of ≥7 days within 6 months of initiation); interrupters (gap ≥7 days, resumed treatment); discontinuers (stopped for ≥7 days, not resumed). A quota of approximately 50 respondents per persistence category was set. Results: A total of 154 respondents (52 continuers, 52 interrupters, 50 discontinuers) completed the survey. Mean age was 51.4 years; 51.9% male. Continuers were more likely to report their views being considered during initiation, and less likely to report a sense of failure. Concerns included insulin dependence (64.3% agree/strongly agree), frequent blood glucose monitoring (55.2%), costs/ability to pay (53.9%), fears of or mistakes during self-injection (52.6%), and weight gain (52.6%). Continuers were motivated by benefits of insulin therapy; experienced or potential side effects were notable factors for interruption/discontinuation. Healthcare provider instruction was indicated as a reason for continuing, stopping, and restarting therapy. Conclusion: Benefits of basal insulin therapy motivated continuers while side effects impacted interruption/discontinuation. Persistence on basal insulin is often influenced by provider actions. Earlier provider intervention upon signs of treatment discontinuation may promote persistence.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States</p>

Kalirai

Ivanova

Pérez-Nieves

et al. 2020

DMSO

View full text Add to dashboard Cite

show abstract

“…Patient-centered care in diabetes involves evaluating individual patients’ unique characteristics, preferences, and abilities to devise a personalized treatment plan and therapeutic goals. Working to better understand patients’ experience with taking diabetes medications, improve the patient-provider relationship to gain patients’ trust, and obtain necessary health care system support for providers can promote adherence to the medication regimen in diabetes ( 10 ).…”

Section: Patient-centered Carementioning

confidence: 99%

Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens

Lahiri

2017

Clinical Diabetes

View full text Add to dashboard Cite

IN BRIEF Caring for people with type 2 diabetes requires a patient-centered approach to treatment targets and medication regimens. Focusing on patients’ individual characteristics, needs, and treatment responses can improve compliance and clinical outcomes. Medication selection can be guided by the mechanisms of action, advantages, disadvantages, and costs of available options; patients’ behavioral and psychological variables, personal preferences, and socioeconomic status also should be taken into account. This article provides an overview of patient-centered and individualized diabetes management, offers pharmacological recommendations for specific clinical scenarios, and describes a complicated case illustrating the patient-centered approach in clinical practice.

show abstract

“…[1,2,3] Improving medication management begins with an accurate exchange of information between the health care providers and the patients. [4,5] Therefore, new interventions are needed to move beyond these known barriers and help adherence. [5] Second, prior research has shown that individuals living with DM have low rate of compliance with lifestyle interventions.…”

Section: Introductionmentioning

confidence: 99%

“…[4,5] Therefore, new interventions are needed to move beyond these known barriers and help adherence. [5] Second, prior research has shown that individuals living with DM have low rate of compliance with lifestyle interventions. [6,7] Given that individuals with DM are more likely to have other risk factors, lifestyle intervention remains a crucial component of their care.…”

Section: Introductionmentioning

confidence: 99%

Use of Wearable Device among Adults in the US with Self-reported Diabetes Mellitus: An Analysis of the 2019 Health Information National Trends Survey

Kekere¹,

Onyeaka²,

Fatoki³

et al. 2020

JPAR

View full text Add to dashboard Cite

Objective: To evaluate the prevalence, patterns, and sociodemographic predictors of wearable device use among individuals with self-reported diabetes mellitus. Methods: Data for our analysis was drawn from cycle 3 (2019) of the 5th edition of the Health Information National Trends Survey (HINTS 5). Descriptive statistics were used to evaluate the demographic characteristics, prevalence, and frequency of wearable device use among individuals with diabetes mellitus. Multivariable logistic regression was used to identify the sociodemographic predictors of wearable device use. Results: We identified 1149 individuals who self-reported diabetes mellitus. Of these, 51.2% were females, 59.3% were white, and 51.6% had less than a college education. The prevalence of wearable device use was 20%. Further, a sizable proportion (86.1%) of the wearable device users were willing to share information from their wearable devices with their healthcare provider, and almost half of them (43.4%) reported daily use of these devices in the past 1-month. Significant sociodemographic predictors of wearable device use include age, income, and level of education. Conclusion: Our results highlight the feasibility and acceptability of using wearable devices to deliver evidence-based health care to individuals with diabetes. Future interventions should consider the scalability of these tools and how to reach those subgroups of individuals with diabetes mellitus to whom current technologies may be unavailable.

show abstract

Seeing the Person, Not the Illness: Promoting Diabetes Medication Adherence Through Patient-Centered Collaboration

Cited by 27 publications

References 54 publications

<p>Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States</p>

<p>Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States</p>

Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens

Use of Wearable Device among Adults in the US with Self-reported Diabetes Mellitus: An Analysis of the 2019 Health Information National Trends Survey

Contact Info

Product

Resources

About